This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD).
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD).
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
-
Om Research LLC, Lancaster, California, United States, 93534
Peak Gastroenterology Associates, Colorado Springs, Colorado, United States, 80907
J&A Clinical Research, Doral, Florida, United States, 33173
Miami Beach Clinical Research Center, Miami Beach, Florida, United States, 33141
Homestead Associates in Research, Inc., Miami, Florida, United States, 33033
Allied Biomedical Research Institute, Inc, Miami, Florida, United States, 33155
Eminat Research Group, Miramar, Florida, United States, 33027
Digestive and Liver Center of Florida, Orlando, Florida, United States, 32825
Louisiana Research Center - GastroIntestinal Associates, Shreveport, Louisiana, United States, 71105
Gastroenterology Associates of Western Michigan, P.L.C., Wyoming, Michigan, United States, 49519
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
16 Years to 80 Years
ALL
No
Hoffmann-La Roche,
Clinical Trials, STUDY_DIRECTOR, Hoffmann-La Roche
2028-12-31